Fig. 3
From: Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials
Kaplan–Meier plots of PFS according to the RESIST and Choi criteria. a PFS in patients who received one or two previous lines of therapy versus those who received three or more lines of therapy according to the RESIST. The PFS of patients who received one or two previous lines of chemotherapy (n = 7; median, 2.8 months) showed similar PFS as patients who received three or more lines (n = 10, median, 1.5 months; HR, 0.839; P = 0.739). b PFS of patients with SD and PD based on RESIST. Patients showing SD by RECIST (n = 10; median, 3.9 months) had significantly longer median PFS than those with PD (n = 11; median, 0.93 months; P < 0.0001). c PFS of patients with PR and SD/PD based on the Choi criteria. Patients showing PR according to the Choi criteria (n = 4; median, 5.9 months) also showed statistically longer PFS than the other patients (total n = 17; SD patients, n = 6 and PD patients, n = 11, 1.5 months; HR, 0.186; 95 % CI, 0.04–0.85; P = 0.03)